Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.
You may also be interested in...
Mylan Launches Generic Paxil CR
Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.
Mylan Launches Generic Paxil CR
Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.
Generic Keppra Set For Launch In November 2008 After UCB Settles
Mylan could launch generic versions of the antiepileptic Nov. 1, 2008, two months ahead of anticipated exclusivity expiry of levetiracetam.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: